Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + VMP in newly diagnosed multiple myeloma (ALCYONE)
NCT02195479Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression Free Survival at 2.4 years. Started Dec 2014; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02195479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195479.